(Reuters) -Eli Lilly said on Wednesday it will invest more than $1.2 billion to expand its manufacturing site in Puerto Rico, as the drugmaker looks to increase its U.S. production capacity to hedge against potential tariffs.

The revamped facility in Carolina, Puerto Rico will help manufacture Lilly’s weight-loss pill, orforglipron, for which the company expects to submit a marketing application to global regulators by end of this year.

Global pharmaceutical companies have been increasing U.S. investments to bolster production capacity after President Donald Trump urged the industry to make more medicines domestically rather than importing active ingredients or finished medicines.

The investment is part of Lilly’s previously announced $50 billion plan to expand its U.S. manufacturing ca

See Full Page